IBJNews

CNO Financial's quarterly earnings, revenue rise

Back to TopCommentsE-mailPrintBookmark and Share

Insurance holding company CNO Financial Group Inc. said Tuesday that its third-quarter earnings jumped nearly four times over last year's third quarter, but mostly because of a one-time gain from the release of an allowance for deferred tax assets.

The Carmel-based parent of Bankers Life, Washington National and Penn insurance companies posted earnings of $196 million, or 66 cents per share, compared with $49.4 million, or 17 cents per share, a year ago.

The results included the release of $143 million of tax valuation allowance.

Net operating income, which excludes the allowance and other one-time items, was $46.5 million, or 17 cents per share, compared with $47.1 million, or 16 cents per share, a year ago.

The results matched the 17 cents per share expected by analysts surveyed by FactSet.

Revenue fell 5.7 percent, to $992.3 million from $1.05 billion.

Analysts were expecting $1.01 billion.

Revenue from insurance policies was nearly flat at $673.5 million, compared with $674.5 million. Net investment income from general accounts rose 3.6 percent, to $338.2 million, while investments from policyholder and reinsurer accounts and other sources resulted in a loss of $54.9 million. Last year, the investments earned $43.3 million.

CNO’s Chicago-based Bankers Life unit and Philadelphia-based Colonial Penn unit saw sales increase 10 percent in the quarter compared to a year ago. Sales at the Carmel-based Washington National unit rose 3 percent.

Realized investment gains rose 19 percent, to $33.5 million.

CNO announced the results after markets closed. Shares fell 30 cents Tuesday, or 5 percent, to close at $5.65 per share. The company's stock price has fallen 16.7 percent since the beginning of the year.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. So, Pence wants the federal government to ignore the 2008 law that allows children from these countries to argue for asylum in front of a judge. How did this guy become governor? And how is that we'll soon be subjected to repeatedly seeing him on TV being taken seriously as a presidential candidate? Am I in Bizzaro-U.S.A.?

  2. "And the most rigorous studies of one-year preschool programs have shown short-term benefits that fade out in a few years or no benefits at all." So we are going down a path that seems to have proven not to work very well. Right intention, wrong approach?

  3. Well for Dunkin Donuts it might say that even a highly popular outlet can't make a poorly sited location work. That little strip has seen near constant churn for years.

  4. Years ago, the Pharmaceutical and Medical Device companies shifted their research investment away from Medical Institutions to focus more on private research centers, primarily because of medical institution inefficiencies in initiating clinical studies and their inability/commitment to enroll the needed number of patients in these studies. The protracted timelines of the medical institutions were prompting significant delays in the availability of new drug and medical device entities for patients and relatedly, higher R and D expenditures to the commercial industry because of these delays. While the above stated IU Health "ratio is about $2.50 in federal funding for every $1 in industry funding", the available funding is REVERSED as commercial R and D (primarily Phase I-IV clinical work)runs $2.50 to $1 for available federal funding ($76.8B to $30.9B in 2011). The above article significatly understated the available R and D funding from industry......see the Pharma and Medical Device industry websites. Clearly, if medical institutions like IU Health wish to attract more commercial studies, they will need to become more competitive with private clinical sites in their ability to be more efficient and in their commitment to meet study enrollment goals on time. Lastly, to the reference to the above Washington Post article headlined “As drug industry’s influence over research grows, so does the potential for bias", lacks some credibility as both FDA and Institutional Institutional Review Boards must approve the high proportion of these studies before studies are started. This means that both study safety and science must be approved by both entities.

  5. ChIeF and all the other critics – better is better no matter what. Get over it; they are doing better despite you ?

ADVERTISEMENT